Details of the Drug Reposition

General Information of This Drug (ID: DMP45ME)

Drug Name
Lisocabtagene maraleucel   DMP45ME
Synonyms JCAR017
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Large B-cell lymphoma DISZAPEJ 2A81 Approved [1]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Follicular lymphoma DISVEUR6 2A80 Phase 2 [2]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 2 [3]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Precursor B-lymphoblastic neoplasm DISI16IJ 2A70 Phase 1/2 [4]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2 ClinicalTrials.gov (NCT03484702) Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
3 ClinicalTrials.gov (NCT03310619) A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
4 ClinicalTrials.gov (NCT03743246) A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)